Aura Biosciences (NASDAQ:AURA) Stock Rating Upgraded by Lifesci Capital

Lifesci Capital upgraded shares of Aura Biosciences (NASDAQ:AURA) to a strong-buy rating in a research note issued to investors on Monday, Zacks.com reports.

A number of other research firms have also recently commented on AURA. HC Wainwright began coverage on Aura Biosciences in a report on Thursday, July 25th. They issued a buy rating and a $21.00 price objective on the stock. JMP Securities restated a market outperform rating and issued a $19.00 target price on shares of Aura Biosciences in a research report on Wednesday, August 28th.

Aura Biosciences Stock Up 12.2 %

NASDAQ AURA opened at $9.02 on Monday. The business’s fifty day simple moving average is $8.32 and its 200-day simple moving average is $7.85. The firm has a market cap of $446.88 million, a PE ratio of -4.85 and a beta of 0.36. Aura Biosciences has a 52 week low of $5.99 and a 52 week high of $12.35.

Aura Biosciences (NASDAQ:AURA) last issued its earnings results on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.04. Research analysts expect that Aura Biosciences will post -1.71 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in AURA. American Century Companies Inc. acquired a new stake in shares of Aura Biosciences in the second quarter valued at $119,000. American International Group Inc. boosted its holdings in shares of Aura Biosciences by 27.4% in the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after acquiring an additional 3,782 shares during the period. Virtu Financial LLC purchased a new position in Aura Biosciences during the 1st quarter worth $144,000. Trexquant Investment LP grew its holdings in shares of Aura Biosciences by 64.5% during the fourth quarter. Trexquant Investment LP now owns 17,362 shares of the company’s stock worth $154,000 after buying an additional 6,809 shares during the last quarter. Finally, Rhumbline Advisers grew its stake in shares of Aura Biosciences by 39.6% in the 2nd quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after purchasing an additional 18,011 shares during the last quarter. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.